Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers.

Talwelkar SS, Nagaraj AS, Devlin JR, Hemmes A, Potdar S, Kiss EA, Saharinen P, Salmenkivi K, Mäyränpää MI, Wennerberg K, Verschuren EW.

Mol Cancer Ther. 2019 Oct;18(10):1863-1874. doi: 10.1158/1535-7163.MCT-18-0573. Epub 2019 Jul 18.

PMID:
31320402
2.

Targeting β1-integrin inhibits vascular leakage in endotoxemia.

Hakanpaa L, Kiss EA, Jacquemet G, Miinalainen I, Lerche M, Guzmán C, Mervaala E, Eklund L, Ivaska J, Saharinen P.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6467-E6476. doi: 10.1073/pnas.1722317115. Epub 2018 Jun 25.

3.

Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and β1-integrin activation.

Pekkonen P, Alve S, Balistreri G, Gramolelli S, Tatti-Bugaeva O, Paatero I, Niiranen O, Tuohinto K, Perälä N, Taiwo A, Zinovkina N, Repo P, Icay K, Ivaska J, Saharinen P, Hautaniemi S, Lehti K, Ojala PM.

Elife. 2018 May 1;7. pii: e32490. doi: 10.7554/eLife.32490.

4.

SnapShot: Angiopoietins and Their Functions.

Saharinen P, Leppänen VM, Alitalo K.

Cell. 2017 Oct 19;171(3):724-724.e1. doi: 10.1016/j.cell.2017.10.009.

5.

Therapeutic targeting of the angiopoietin-TIE pathway.

Saharinen P, Eklund L, Alitalo K.

Nat Rev Drug Discov. 2017 Sep;16(9):635-661. doi: 10.1038/nrd.2016.278. Epub 2017 May 19. Review.

PMID:
28529319
6.

Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization.

Leppänen VM, Saharinen P, Alitalo K.

Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4376-4381. doi: 10.1073/pnas.1616166114. Epub 2017 Apr 10.

7.

Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems.

Eklund L, Kangas J, Saharinen P.

Clin Sci (Lond). 2017 Jan 1;131(1):87-103. Review.

8.

Novel Angiogenesis Markers as Long-Term Prognostic Factors in Patients With Renal Cell Cancer.

Lampinen AM, Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Saharinen P, Kellokumpu-Lehtinen PI.

Clin Genitourin Cancer. 2017 Feb;15(1):e15-e24. doi: 10.1016/j.clgc.2016.07.008. Epub 2016 Jul 21.

PMID:
27554585
9.

Tie1 controls angiopoietin function in vascular remodeling and inflammation.

Korhonen EA, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, Fang S, D'Amico G, Sipilä TJ, Lohela M, Strandin T, Vaheri A, Ylä-Herttuala S, Koh GY, McDonald DM, Alitalo K, Saharinen P.

J Clin Invest. 2016 Sep 1;126(9):3495-510. doi: 10.1172/JCI84923. Epub 2016 Aug 22.

10.

Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation.

Kim M, Allen B, Korhonen EA, Nitschké M, Yang HW, Baluk P, Saharinen P, Alitalo K, Daly C, Thurston G, McDonald DM.

J Clin Invest. 2016 Sep 1;126(9):3511-25. doi: 10.1172/JCI84871. Epub 2016 Aug 22.

11.

Critical requirement of VEGF-C in transition to fetal erythropoiesis.

Fang S, Nurmi H, Heinolainen K, Chen S, Salminen E, Saharinen P, Mikkola HK, Alitalo K.

Blood. 2016 Aug 4;128(5):710-20. doi: 10.1182/blood-2015-12-687970. Epub 2016 Jun 24.

PMID:
27343251
12.

Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion.

Tuuminen R, Holmström E, Raissadati A, Saharinen P, Rouvinen E, Krebs R, Lemström KB.

Transpl Immunol. 2016 Jul;37:40-45. doi: 10.1016/j.trim.2016.05.001. Epub 2016 May 4.

PMID:
27155462
13.

Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.

Rautiola J, Lampinen A, Mirtti T, Ristimäki A, Joensuu H, Bono P, Saharinen P.

PLoS One. 2016 Apr 21;11(4):e0153745. doi: 10.1371/journal.pone.0153745. eCollection 2016.

14.

VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption.

Nurmi H, Saharinen P, Zarkada G, Zheng W, Robciuc MR, Alitalo K.

EMBO Mol Med. 2015 Nov;7(11):1418-25. doi: 10.15252/emmm.201505731.

15.

Blocking integrin inactivation as an anti-angiogenic therapy.

Saharinen P, Ivaska J.

EMBO J. 2015 May 12;34(10):1293-5. doi: 10.15252/embj.201591504. Epub 2015 Mar 31. No abstract available.

16.

Endothelial destabilization by angiopoietin-2 via integrin β1 activation.

Hakanpaa L, Sipila T, Leppanen VM, Gautam P, Nurmi H, Jacquemet G, Eklund L, Ivaska J, Alitalo K, Saharinen P.

Nat Commun. 2015 Jan 30;6:5962. doi: 10.1038/ncomms6962.

17.

The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis.

Chen HI, Sharma B, Akerberg BN, Numi HJ, Kivelä R, Saharinen P, Aghajanian H, McKay AS, Bogard PE, Chang AH, Jacobs AH, Epstein JA, Stankunas K, Alitalo K, Red-Horse K.

Development. 2014 Dec;141(23):4500-12. doi: 10.1242/dev.113639. Epub 2014 Nov 5.

18.

VEGF-C and aortic cardiomyocytes guide coronary artery stem development.

Chen HI, Poduri A, Numi H, Kivela R, Saharinen P, McKay AS, Raftrey B, Churko J, Tian X, Zhou B, Wu JC, Alitalo K, Red-Horse K.

J Clin Invest. 2014 Nov;124(11):4899-914. doi: 10.1172/JCI77483. Epub 2014 Oct 1.

19.

The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel.

Aspelund A, Tammela T, Antila S, Nurmi H, Leppänen VM, Zarkada G, Stanczuk L, Francois M, Mäkinen T, Saharinen P, Immonen I, Alitalo K.

J Clin Invest. 2014 Sep;124(9):3975-86. doi: 10.1172/JCI75395. Epub 2014 Jul 25.

20.

Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts.

Syrjälä SO, Tuuminen R, Nykänen AI, Raissadati A, Dashkevich A, Keränen MA, Arnaudova R, Krebs R, Leow CC, Saharinen P, Alitalo K, Lemström KB.

Am J Transplant. 2014 May;14(5):1096-108. doi: 10.1111/ajt.12672. Epub 2014 Apr 7.

21.

Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy.

D'Amico G, Korhonen EA, Anisimov A, Zarkada G, Holopainen T, Hägerling R, Kiefer F, Eklund L, Sormunen R, Elamaa H, Brekken RA, Adams RH, Koh GY, Saharinen P, Alitalo K.

J Clin Invest. 2014 Feb;124(2):824-34. doi: 10.1172/JCI68897. Epub 2014 Jan 16.

22.

Receptor tyrosine kinase-mediated angiogenesis.

Jeltsch M, Leppänen VM, Saharinen P, Alitalo K.

Cold Spring Harb Perspect Biol. 2013 Sep 1;5(9). pii: a009183. doi: 10.1101/cshperspect.a009183. Review.

23.

Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function.

Tuuminen R, Nykänen AI, Saharinen P, Gautam P, Keränen MA, Arnaudova R, Rouvinen E, Helin H, Tammi R, Rilla K, Krebs R, Lemström KB.

Am J Transplant. 2013 Aug;13(8):2019-34. doi: 10.1111/ajt.12315. Epub 2013 Jun 14.

24.

Angiopoietin signaling in the vasculature.

Eklund L, Saharinen P.

Exp Cell Res. 2013 May 15;319(9):1271-80. doi: 10.1016/j.yexcr.2013.03.011. Epub 2013 Mar 13. Review.

PMID:
23500414
25.

Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis.

Anisimov A, Tvorogov D, Alitalo A, Leppänen VM, An Y, Han EC, Orsenigo F, Gaál EI, Holopainen T, Koh YJ, Tammela T, Korpisalo P, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Dejana E, Koh GY, Choi C, Saharinen P, Alitalo K.

Circulation. 2013 Jan 29;127(4):424-34. doi: 10.1161/CIRCULATIONAHA.112.127472.

PMID:
23357661
26.

Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses.

Pietilä R, Nätynki M, Tammela T, Kangas J, Pulkki KH, Limaye N, Vikkula M, Koh GY, Saharinen P, Alitalo K, Eklund L.

J Cell Sci. 2012 May 1;125(Pt 9):2212-23. doi: 10.1242/jcs.098020. Epub 2012 Feb 22.

27.

Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis.

Holopainen T, Saharinen P, D'Amico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Heloterä H, Tammela T, Benjamin LE, Ylä-Herttuala S, Leow CC, Koh GY, Alitalo K.

J Natl Cancer Inst. 2012 Mar 21;104(6):461-75. doi: 10.1093/jnci/djs009. Epub 2012 Feb 17.

28.

The yin, the yang, and the angiopoietin-1.

Saharinen P, Alitalo K.

J Clin Invest. 2011 Jun;121(6):2157-9. doi: 10.1172/JCI58196. Epub 2011 May 23.

29.

VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.

Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K.

Trends Mol Med. 2011 Jul;17(7):347-62. doi: 10.1016/j.molmed.2011.01.015. Epub 2011 Apr 12. Review.

PMID:
21481637
30.

Zebrafish Tie-2 shares a redundant role with Tie-1 in heart development and regulates vessel integrity.

Gjini E, Hekking LH, Küchler A, Saharinen P, Wienholds E, Post JA, Alitalo K, Schulte-Merker S.

Dis Model Mech. 2011 Jan;4(1):57-66. doi: 10.1242/dmm.005033. Epub 2010 Nov 2.

31.

Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development.

Saharinen P, Helotera H, Miettinen J, Norrmen C, D'Amico G, Jeltsch M, Langenberg T, Vandevelde W, Ny A, Dewerchin M, Carmeliet P, Alitalo K.

Genes Dev. 2010 May;24(9):875-80. doi: 10.1101/gad.565010.

32.

How do angiopoietins Tie in with vascular endothelial growth factors?

Saharinen P, Bry M, Alitalo K.

Curr Opin Hematol. 2010 May;17(3):198-205. doi: 10.1097/MOH.0b013e3283386673. Review.

PMID:
20375888
33.

Liprin (beta)1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity.

Norrmén C, Vandevelde W, Ny A, Saharinen P, Gentile M, Haraldsen G, Puolakkainen P, Lukanidin E, Dewerchin M, Alitalo K, Petrova TV.

Blood. 2010 Jan 28;115(4):906-9. doi: 10.1182/blood-2009-03-212274. Epub 2009 Nov 30.

34.

Loss of endothelial Tie1 receptor impairs lymphatic vessel development-brief report.

D'Amico G, Korhonen EA, Waltari M, Saharinen P, Laakkonen P, Alitalo K.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):207-9. doi: 10.1161/ATVBAHA.109.196618. Epub 2009 Nov 12.

PMID:
19910638
35.

Recessive primary congenital lymphoedema caused by a VEGFR3 mutation.

Ghalamkarpour A, Holnthoner W, Saharinen P, Boon LM, Mulliken JB, Alitalo K, Vikkula M.

J Med Genet. 2009 Jun;46(6):399-404. doi: 10.1136/jmg.2008.064469. Epub 2009 Mar 15.

PMID:
19289394
36.

Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts.

Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, Olsen BR, Alitalo K.

Nat Cell Biol. 2008 May;10(5):527-37. doi: 10.1038/ncb1715. Epub 2008 Apr 20.

PMID:
18425119
37.

Transcriptomal comparison of human dermal lymphatic endothelial cells ex vivo and in vitro.

Wick N, Saharinen P, Saharinen J, Gurnhofer E, Steiner CW, Raab I, Stokic D, Giovanoli P, Buchsbaum S, Burchard A, Thurner S, Alitalo K, Kerjaschki D.

Physiol Genomics. 2007 Jan 17;28(2):179-92.

PMID:
17234577
38.

Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state.

Kurzer JH, Saharinen P, Silvennoinen O, Carter-Su C.

Mol Cell Biol. 2006 Sep;26(17):6381-94.

39.

Signaling and functions of angiopoietin-1 in vascular protection.

Brindle NP, Saharinen P, Alitalo K.

Circ Res. 2006 Apr 28;98(8):1014-23.

40.

Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2.

Saharinen P, Kerkelä K, Ekman N, Marron M, Brindle N, Lee GM, Augustin H, Koh GY, Alitalo K.

J Cell Biol. 2005 Apr 25;169(2):239-43.

41.

The Janus kinases (Jaks).

Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ.

Genome Biol. 2004;5(12):253. Epub 2004 Nov 30. Review.

42.

Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation.

Saharinen P, Tammela T, Karkkainen MJ, Alitalo K.

Trends Immunol. 2004 Jul;25(7):387-95. Review. No abstract available.

PMID:
15207507
43.

Molecular regulation of lymphangiogenesis.

Saharinen P, Petrova TV.

Ann N Y Acad Sci. 2004 Apr;1014:76-87. Review.

PMID:
15153422
44.

Double target for tumor mass destruction.

Saharinen P, Alitalo K.

J Clin Invest. 2003 May;111(9):1277-80. No abstract available.

45.

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Saharinen P, Vihinen M, Silvennoinen O.

Mol Biol Cell. 2003 Apr;14(4):1448-59.

47.

Effects of hyperactive Janus kinase 2 signaling in mammary epithelial cells.

Olsen H, Hedengran Faulds MA, Saharinen P, Silvennoinen O, Haldosén LA.

Biochem Biophys Res Commun. 2002 Aug 9;296(1):139-44.

PMID:
12147240
48.

Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.

Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O.

Mol Cell Biol. 2002 May;22(10):3316-26.

49.

The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner.

Ekman N, Arighi E, Rajantie I, Saharinen P, Ristimäki A, Silvennoinen O, Alitalo K.

Oncogene. 2000 Aug 24;19(36):4151-8.

50.

Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.

Saharinen P, Takaluoma K, Silvennoinen O.

Mol Cell Biol. 2000 May;20(10):3387-95.

Supplemental Content

Loading ...
Support Center